T-cell margination after first glofitamab infusion is dose and response dependent. (A) Flow cytometric analysis of peripheral CD19⁺ B cells and CD3⁺ T cells before obinutuzumab pretreatment (C1D-7, predose) and before the first glofitamab infusion (C1D1, predose; n = 110 pairs). Dotted line indicates 5 cells/µL. (B) Graphs represent log₂ fold change (Log2FC) from baseline (C1D1 predose) of peripheral CD8⁺ T-cell subsets at indicated time points during C1, as measured by flow cytometry. Error bars indicate confidence intervals, dotted lines indicate baseline levels, and dashed lines indicate twofold change from baseline. (C) Box plots (left) represent Log2FC from baseline (C1D1 predose) of peripheral CD3⁺ T cells at 6 hours’ post–end of infusion (6 H EOI; top) and end of C1 (bottom) time points, as measured by flow cytometry, in relation to the best overall response (BOR). Scatter plots (right) indicate the correlation between Log2FC from baseline (C1D1 predose) of peripheral CD3⁺ T cells and the administered glofitamab dose (milligrams) at 6 H EOI (top) and end of C1 (bottom) time points. Data in panels B and C are from n = 119 patients with evaluable flow cytometry data. Colors indicate BOR categories. P value represents CR vs PR/stable disease (SD)/progressive disease (PD) and was not adjusted for log(glofitamab dose) and IPI category. C, cycle; D, day; ND, not disclosed; RMSE, root mean square error.